| pubmed-article:20207610 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20207610 | lifeskim:mentions | umls-concept:C0599755 | lld:lifeskim |
| pubmed-article:20207610 | lifeskim:mentions | umls-concept:C0917713 | lld:lifeskim |
| pubmed-article:20207610 | lifeskim:mentions | umls-concept:C0001617 | lld:lifeskim |
| pubmed-article:20207610 | lifeskim:mentions | umls-concept:C1524063 | lld:lifeskim |
| pubmed-article:20207610 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:20207610 | pubmed:dateCreated | 2010-11-15 | lld:pubmed |
| pubmed-article:20207610 | pubmed:abstractText | The use of corticosteroids for treatment of Duchenne and Becker muscular dystrophy in clinical practice from 1991 through 2005 was reviewed in a large population-based cohort (MD STARnet) of boys in 4 regional sites and 6 clinics of the United States. Corticosteroid use increased from 20% (11 of 56 individuals) in 1991 to 44% (93 of 218 individuals) in 2005. Average use varied by site and ranged from 15% to 49%. The median age of corticosteroid initiation was 6.9 years (range, 3.7-17.4 years). Dosage and growth information was available for 102 participants and showed a median dose as 0.729 mg/kg for prednisone and 0.831 mg/kg for deflazacort. T. The most common reasons that corticosteroids were discontinued included weight gain, behavioral side effects, and loss of ambulation, resulting in full-time wheelchair use. Substantial variations in clinical practice were identified among study sites. | lld:pubmed |
| pubmed-article:20207610 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20207610 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20207610 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20207610 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20207610 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20207610 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20207610 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:20207610 | pubmed:issn | 1708-8283 | lld:pubmed |
| pubmed-article:20207610 | pubmed:author | pubmed-author:CiafaloniEmma... | lld:pubmed |
| pubmed-article:20207610 | pubmed:author | pubmed-author:MathewsKather... | lld:pubmed |
| pubmed-article:20207610 | pubmed:author | pubmed-author:CunniffChrist... | lld:pubmed |
| pubmed-article:20207610 | pubmed:author | pubmed-author:MillerLisa... | lld:pubmed |
| pubmed-article:20207610 | pubmed:author | pubmed-author:MeaneyF... | lld:pubmed |
| pubmed-article:20207610 | pubmed:author | pubmed-author:RomittiPaul... | lld:pubmed |
| pubmed-article:20207610 | pubmed:author | pubmed-author:DruschelCharl... | lld:pubmed |
| pubmed-article:20207610 | pubmed:author | pubmed-author:MillerTimothy... | lld:pubmed |
| pubmed-article:20207610 | pubmed:author | pubmed-author:FoxDeborah... | lld:pubmed |
| pubmed-article:20207610 | pubmed:author | pubmed-author:JamesKatherin... | lld:pubmed |
| pubmed-article:20207610 | pubmed:author | pubmed-author:CampbellKimbe... | lld:pubmed |
| pubmed-article:20207610 | pubmed:author | pubmed-author:MatthewsDenni... | lld:pubmed |
| pubmed-article:20207610 | pubmed:author | pubmed-author:PandyaShreeS | lld:pubmed |
| pubmed-article:20207610 | pubmed:author | pubmed-author:MD STARnet | lld:pubmed |
| pubmed-article:20207610 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20207610 | pubmed:volume | 25 | lld:pubmed |
| pubmed-article:20207610 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20207610 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20207610 | pubmed:pagination | 1319-24 | lld:pubmed |
| pubmed-article:20207610 | pubmed:meshHeading | pubmed-meshheading:20207610... | lld:pubmed |
| pubmed-article:20207610 | pubmed:meshHeading | pubmed-meshheading:20207610... | lld:pubmed |
| pubmed-article:20207610 | pubmed:meshHeading | pubmed-meshheading:20207610... | lld:pubmed |
| pubmed-article:20207610 | pubmed:meshHeading | pubmed-meshheading:20207610... | lld:pubmed |
| pubmed-article:20207610 | pubmed:meshHeading | pubmed-meshheading:20207610... | lld:pubmed |
| pubmed-article:20207610 | pubmed:meshHeading | pubmed-meshheading:20207610... | lld:pubmed |
| pubmed-article:20207610 | pubmed:meshHeading | pubmed-meshheading:20207610... | lld:pubmed |
| pubmed-article:20207610 | pubmed:meshHeading | pubmed-meshheading:20207610... | lld:pubmed |
| pubmed-article:20207610 | pubmed:meshHeading | pubmed-meshheading:20207610... | lld:pubmed |
| pubmed-article:20207610 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20207610 | pubmed:articleTitle | Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy. | lld:pubmed |
| pubmed-article:20207610 | pubmed:affiliation | Department of Physical Medicine & Rehabilitation, University of Colorado School of Medicine and The Children's Hospital, Denver, CO 80045, USA. matthews.dennis@tchden.org | lld:pubmed |
| pubmed-article:20207610 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20207610 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
